1. Scrip
  2. >>Focus On Asia

China's Connect Eyes Partnerships To Globalize Dermatitis Biologic

CEO Wants To Unlock Main Value Outside Home Market

 
• By Brian Yang

Watch out Sanofi. US- and China-based Connect BioPharma is looking to position its novel biologic for atopic dermatitis to compete head-on with best-selling Dupixent both inside and outside China in an increasingly crowded space, says co-founder and CEO Wei Zheng in an exclusive interview with Scrip.

Atopic dermatitis
Connect BioPharma eyes partnerships to bring novel biologics from China to global market • Source: Shutterstock

Some 10 years after its founding, China- and US-based Connect Biopharma Holdings Ltd. is readying a major regulatory filing for its lead candidate, a novel anti-interleukin 4 receptor alpha antibody for moderate to severe atopic dermatitis it hopes will be able to take on Sanofi's blockbuster biologics in the space.

The atopic dermatitis area is seeing increasing activity from conventional topical treatments to biologics, from local to systemic therapies, and is a segment that has attracted a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.